Chaurasia Mohini, Singh Romi, Sur Srija, Flora S J S
Era College of Pharmacy, Era University, Lucknow, Uttar Pradesh, India.
Front Pharmacol. 2023 Jul 28;14:1184472. doi: 10.3389/fphar.2023.1184472. eCollection 2023.
Breast cancer is one of the most diagnosed solid cancers globally. Extensive research has been going on for decades to meet the challenges of treating solid tumors with selective compounds. This article aims to summarize the therapeutic agents which are either being used or are currently under approval for use in the treatment or mitigation of breast cancer by the US FDA, to date. A structured search of bibliographic databases for previously published peer-reviewed research papers on registered molecules was explored and data was sorted in terms of various categories of drugs used in first line/adjuvant therapy for different stages of breast cancer. We included more than 300 peer-reviewed papers, including both research and reviews articles, in order to provide readers an useful comprehensive information. A list of 39 drugs are discussed along with their current status, dose protocols, mechanism of action, pharmacokinetics, possible side effects, and marketed formulations. Another interesting aspect of the article included focusing on novel formulations of these drugs which are currently in clinical trials or in the process of approval. This exhaustive review thus shall be a one-stop solution for researchers who are working in the areas of formulation development for these drugs.
乳腺癌是全球诊断最多的实体癌之一。数十年来，人们一直在进行广泛研究，以应对用选择性化合物治疗实体瘤的挑战。本文旨在总结截至目前美国食品药品监督管理局（US FDA）已批准使用或正在批准用于治疗或缓解乳腺癌的治疗药物。我们对文献数据库进行了结构化检索，以查找先前发表的关于已注册分子的同行评审研究论文，并根据用于乳腺癌不同阶段一线/辅助治疗的各类药物对数据进行了分类整理。为了给读者提供有用的全面信息，我们纳入了300多篇同行评审论文，包括研究论文和综述文章。文中讨论了39种药物的清单，以及它们的当前状态、剂量方案、作用机制、药代动力学、可能的副作用和上市剂型。本文另一个有趣的方面是关注这些药物目前正在进行临床试验或审批过程中的新型剂型。因此，对于从事这些药物剂型开发领域研究的人员来说，这一详尽的综述将是一个一站式的解决方案。
